This study investigates whether the BDNF Val66Met (rs6265) and ATP2A2 rs1860561 polymorphisms are associated with a differential therapeutic response to low-dose empagliflozin in patients with heart failure. The gene discussed is ATP2A2; the disease is heart failure.